Illumina Collaborating With Pharmaceutical Firms on KRAS Cancer Diagnostics

MT Newswires Live

2025/09/23

Illumina (ILMN) said Tuesday it is working with several global drugmakers to develop companion diagnostics on its TruSight Oncology test to target KRAS mutations.

The company said the partnerships aim to expand diagnostic claims that can help match cancer patients with targeted treatments and clinical trials.

KRAS is among the most frequently altered oncogenes, and identifying its variants is considered critical for selecting appropriate therapies, according to the company.

Illumina said the initiative builds on its pipeline of companion diagnostics under development with pharmaceutical companies.

Price: 102.34, Change: +0.85, Percent Change: +0.84

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2569837716"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569837716\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569837716?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-23 22:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569837716","market":"nz","top_or_hot":-1,"title":"Illumina Collaborating With Pharmaceutical Firms on KRAS Cancer Diagnostics","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ILMN\">Illumina</a> (ILMN) said Tuesday it is working with several global drugmakers to develop companion diagnostics on its TruSight Oncology test to target KRAS mutations.</p><p>The company said the partnerships aim to expand diagnostic claims that can help match cancer patients with targeted treatments and clinical trials.</p><p>KRAS is among the most frequently altered oncogenes, and identifying its variants is considered critical for selecting appropriate therapies, according to the company.</p><p>Illumina said the initiative builds on its pipeline of companion diagnostics under development with pharmaceutical companies.</p><p>Price: 102.34, Change: +0.85, Percent Change: +0.84</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Illumina Collaborating With Pharmaceutical Firms on KRAS Cancer Diagnostics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIllumina Collaborating With Pharmaceutical Firms on KRAS Cancer Diagnostics\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-09-23 22:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ILMN\">Illumina</a> (ILMN) said Tuesday it is working with several global drugmakers to develop companion diagnostics on its TruSight Oncology test to target KRAS mutations.</p><p>The company said the partnerships aim to expand diagnostic claims that can help match cancer patients with targeted treatments and clinical trials.</p><p>KRAS is among the most frequently altered oncogenes, and identifying its variants is considered critical for selecting appropriate therapies, according to the company.</p><p>Illumina said the initiative builds on its pipeline of companion diagnostics under development with pharmaceutical companies.</p><p>Price: 102.34, Change: +0.85, Percent Change: +0.84</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ILMN","symbol_name":"Illumina","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2569837716","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569837716","pubTimestamp":1758636396,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Illumina  said Tuesday it is working with several global drugmakers to develop companion diagnostics on its TruSight Oncology test to target KRAS mutations.The company said the partnerships aim to expand diagnostic claims that can help match cancer patients with targeted treatments and clinical trials.KRAS is among the most frequently altered oncogenes, and identifying its variants is considered critical for selecting appropriate therapies, according to the company.Illumina said the initiative builds on its pipeline of companion diagnostics under development with pharmaceutical companies.Price: 102.34, Change: +0.85, Percent Change: +0.84","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"ILMN":"Illumina"},"translate_title":"Illumina与制药公司合作开发KRAS癌症诊断","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":1.5},"content_text":"Illumina (ILMN) said Tuesday it is working with several global drugmakers to develop companion diagnostics on its TruSight Oncology test to target KRAS mutations.The company said the partnerships aim to expand diagnostic claims that can help match cancer patients with targeted treatments and clinical trials.KRAS is among the most frequently altered oncogenes, and identifying its variants is considered critical for selecting appropriate therapies, according to the company.Illumina said the initiative builds on its pipeline of companion diagnostics under development with pharmaceutical companies.Price: 102.34, Change: +0.85, Percent Change: +0.84","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}